


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, said compound having the Formula:



where

Y is  $\text{CR}^1$ , O, S, or  $\text{NR}^2$ ;

W is  $\text{CR}^3$ , N,  $\text{NR}^4$ , S, or O, provided that W is  $\text{NR}^4$ , S, or O when Y is  $\text{CR}^1$  and W is  $\text{CR}^3$  or N when Y is  $\text{NR}^2$ ;

$\text{R}^3$  is H,  $\text{NH}_2$ , F, Cl, methyl or substituted methyl;

$\text{R}^4$  is H, methyl or substituted methyl;

$\text{R}^1$  and  $\text{R}^2$  [[are]] is independently H, OH, an amine protecting group,  $\text{Z}_n\text{-NR}^a\text{R}^b$ ,  $\text{Z}_n\text{-NR}^a(\text{C}=\text{O})\text{R}^b$ ,  $\text{Z}_n\text{-SO}_2\text{R}^a$ ,  $\text{Z}_n\text{-SOR}^a$ ,  $\text{Z}_n\text{-SR}^a$ ,  $\text{Z}_n\text{-OR}^a$ ,  $\text{Z}_n\text{-(C}=\text{O)}\text{R}^a$ ,  $\text{Z}_n\text{-(C}=\text{O)}\text{OR}^a$ ,  $\text{Z}_n\text{-O-(C}=\text{O)}\text{R}^a$ , alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $\text{Z}_n\text{-cycloalkyl}$  wherein said cycloalkyl is saturated or partially unsaturated,

$\text{Z}_n\text{-heterocycloalkyl}$  wherein said heterocycloalkyl is saturated or partially unsaturated, or  $\text{Z}_n\text{-Ar}^1$ , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $\text{Z}_n\text{-cycloalkyl}$ ,  $\text{Z}_n\text{-heterocycloalkyl}$ , and  $\text{Z}_n\text{-Ar}^1$  may be substituted or unsubstituted;

$\text{Ar}^1$  is aryl or heteroaryl, each of which may be substituted or unsubstituted;

$R^a$  and  $R^b$  are independently H, OH, an amine protecting group, an alcohol protecting group, an acid protecting group, a sulfur protecting group, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated,  $Z_n$ -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or  $Z_n$ -Ar<sup>1</sup>, wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl, and  $Z_n$ -Ar<sup>1</sup> may be substituted or unsubstituted, or  $R^a$  and  $R^b$  together with the atoms to which they are both attached form a saturated or partially unsaturated heterocycle ring having 1 or more heteroatoms in said ring, wherein said heterocycle may be substituted or unsubstituted and wherein said heterocycle may be fused to an aromatic ring; Z is alkylene having from 1 to 4 carbons, or alkenylene or alkynylene each having from 2 to 4 carbons, wherein said alkylene, alkenylene, or alkynylene may be substituted or unsubstituted; n is 0 or 1;

U is CR<sup>c</sup>-or-N;

V is CR<sup>c</sup>-or-N;

R<sup>c</sup> is H, F, Cl, methyl or substituted methyl;

X is O, S, SO, SO<sub>2</sub>, NR<sup>5</sup>, C=O, CH<sub>2</sub>, CH<sub>2</sub>Z<sub>n</sub>-OH, or C=NOR<sup>d</sup>;

R<sup>5</sup> is H, methyl, or substituted methyl;

R<sup>d</sup> is H, PO<sub>3</sub>H<sub>2</sub>, SO<sub>3</sub>H<sub>2</sub>, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated,  $Z_n$ -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or  $Z_n$ -Ar<sup>1</sup>, said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl and  $Z_n$ -Ar<sup>1</sup> may be substituted or unsubstituted;

G, [[H]] K, J, and T independently are N or CR<sup>z</sup>, provided that when any of said G, [[H]] K, J, and T are N the total number of G, [[H]] K, J, or T that is N does not exceed 2;

$R^z$  is H, F, Cl, Br,  $CF_3$ ,  $OR^6$ ,  $SR^6$ , lower alkyl ( $C_1$ - $C_4$ ), CN, or  $NR^6R^7$ ;

$R^6$  and  $R^7$  are independently H,  $CF_3$ , lower alkyl ( $C_1$ - $C_4$ ) or lower heteroalkyl ( $C_1$ - $C_4$ );

Q is  $-NR^8CONH-$ ,  $-NHCO-$ ,  $-NR^8SO_2NH-$ ,  $-NHCO_2-$ ,  $-CONR^{11}-$ ;

$R^8$  is H or lower ( $C_1$ - $C_4$ ) alkyl;

$R^{11}$  is H or lower ( $C_1$ - $C_4$ ) alkyl;

$R_x$  is  $-(CR^9R^{10})_m-$ ,  $-O(CR^9R^{10})_m-$ ,  $NH(CR^9R^{10})_m-$ , or  $-S(CR^9R^{10})_m-$  provided that Q is  $-CONR^{11}-$  when  $R^x$  is  $-O(CR^9R^{10})_m-$ ,  $-NH(CR^9R^{10})_m-$ , or  $-S(CR^9R^{10})_m-$ ;

$R^9$  and  $R^{10}$  are independently H, or lower alkyl, or  $R^9$  and  $R^{10}$  together with the atoms to which they are both attached form a cycloalkyl ring which may be saturated or partially unsaturated;

m is 1-3;

$R_y$  is H,  $PO_3H$ , an amine protecting group, an oxygen protecting group, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated,  $Z_n$ -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or  $Z_n-Ar^2$ , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n-Ar^2$  and  $Z_n$ -heterocycloalkyl may be substituted or unsubstituted;

$Ar^2$  is aryl or heteroaryl, each of which may be substituted or unsubstituted, wherein said substitution can be 1-3 substituents independently selected from F, Cl, Br,  $CF_3$ , CN, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl,  $-OR^{12}$ ,  $-SR^{12}$ ,  $-SO_2R^{12}$ ,  $-SO_2NR^{13}R^{12}$ ,  $NR^{13}SO_2R^{12}$ ,  $Z_n$ -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated,  $Z_n$ -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or  $Z_n-Ar^1$ , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl and  $Z_n-Ar^1$  may be substituted or unsubstituted;



$R^{12}$  and  $R^{13}$  are independently H, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl,  $Z_n$ -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated,  $Z_n$ -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or  $Z_n-Ar^1$ , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl,

heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl and  $Z_n$ -Ar<sup>1</sup> may be substituted or unsubstituted;  
 wherein when Ar<sup>2</sup> is substituted with -SO<sub>2</sub>NR<sup>13</sup>R<sup>12</sup>, R<sup>12</sup> and R<sup>13</sup> can form a cycloalkyl ring or heterocycloalkyl ring that may be substituted or unsubstituted wherein said substitution can be substituents selected from alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated, -COR<sup>12</sup>, -SO<sub>2</sub>R<sup>12</sup>,  $Z_n$ -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or  $Z_n$ -Ar<sup>1</sup>, wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl and  $Z_n$ -Ar<sup>1</sup> may be substituted or unsubstituted;  
 wherein when Q is -CONR<sup>11</sup>, R<sub>y</sub> in combination with R<sup>11</sup> is additionally cycloalkyl ring or heterocycloalkyl ring that may be substituted or unsubstituted with groups selected from alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated,  $Z_n$ -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated,  $Z_n$ -Ar<sup>1</sup>, -COR<sup>14</sup>, or -SO<sub>2</sub>R<sup>14</sup>, wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl,  $Z_n$ -Ar<sup>1</sup>, -COR<sup>14</sup>, and -SO<sub>2</sub>R<sup>14</sup> may be substituted or unsubstituted; and

R<sup>14</sup> is alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl,  $Z_n$ -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated,  $Z_n$ -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or  $Z_n$ -Ar<sup>1</sup>, wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy,  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl, and  $Z_n$ -Ar<sup>1</sup> may be substituted or unsubstituted.

2. (Original) The compound of claim 1, wherein W is CH CH<sub>2</sub> and Y is NR<sup>3</sup>.
3. (Original) The compound of claim 1, wherein G, J, K and T are CR<sup>2</sup>.
4. (Original) The compound of claim 1, wherein X is NH, S, or O.
5. (Original) The compound of claim 1, wherein R<sub>x</sub> is CH<sub>2</sub> and Q is -NHCO-.

6. (Original) The compound of claim 6, wherein  $R_y$  is isopropyl or
7. (Original) The compound of claim 1, wherein  $R_x$  is  $\text{CH}_2$  and Q is  $-\text{NR}^8\text{CONH}-$ .
8. (Original) The compound of claim 8, wherein  $R_y$  is



9. (Original) A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
10. (Withdrawn) A method of treating or preventing a p38-mediated condition in a human or animal, comprising administering to said human or animal a compound of claim 1 in an amount effective to treat or prevent said p38-mediated condition or a pharmaceutical composition comprising said compound.
11. (Withdrawn) The method of claim 11, wherein said p38-mediated condition is inflammatory disease, autoimmune disease, destructive bone disorder, proliferative disorder, infectious disease, viral disease, or neurodegenerative disease.
12. (New) The compound of claim 1, wherein  $R^c$  is H.
13. (New) The compound of claim 1, wherein  $R_x$  is  $-(\text{CR}^9\text{R}^{10})_m-$ .
14. (New) The compound of claim 1, wherein  $R_y$  is  $Z_n$ -cycloalkyl,  $Z_n$ -heterocycloalkyl or  $Z_n\text{-Ar}^2$ .